Cardiac allograft vasculopathy: Pathology, prevention and treatment

Current Opinion in Cardiology

Volumn 21, Issue 2, 2006, Pages 132-137

  Kass, Malek ^a   Haddad, Haissam ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

Cardiac transplantation; Diagnosis; Graft coronary artery disease; Pathophysiology; Therapy

Indexed keywords

ANTITHROMBOCYTIC AGENT; AZATHIOPRINE; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN; EVERLIMUS; HOMOCYSTEINE; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; LEUKOCYTE ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; BRAIN DEATH; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CELLULAR IMMUNITY; CLINICAL TRIAL; CONVENTIONAL ANGIOGRAPHY; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DOSE RESPONSE; FOLLOW UP; HEART FAILURE; HEART INNERVATION; HEART MUSCLE ISCHEMIA; HEART TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LONG TERM CARE; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SURVIVAL;

CAUSE OF DEATH; CORONARY DISEASE; CORONARY VESSELS; CYTOKINES; FIBROMUSCULAR DYSPLASIA; HEART FAILURE, CONGESTIVE; HEART TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; SURVIVAL RATE;

EID: 33748630774     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hco.0000203184.89158.16     Document Type: Review

References (56)

1. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-second Official Adult Heart Transplant Report - 2005. J Heart Lung Transplant 2005; 24:945-955.
2. International Society of Heart and Lung Transplantation (ISHLT) registry. http://www.ishlt.org/registries. [Accessed 29 September 2005]
3. Costanzo MR, Naftel DC, Pritzker MR, et al. Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors. Cardiac Transplant Research Database. J Heart Lung Transplant 1998; 17:744-753.
4. Syeda B, Roedler S, Schukro C, et al. Transplant coronary artery disease: incidence, progression, and interventional revascularization. Int J Cardiol 2005; 104:269-274. This analysis describes data on incidence and progression of allograft CAD.
5. Yeung AC, Davis SF, Hauptman PJ, et al. Incidence and progression of transplant coronary artery disease over 1 year: results of a multicenter trial with use of intravascular ultrasound. Multicenter Intravascular Ultrasound Transplant Study Group. J Heart Lung Transplant 1995; 14 (6 Pt 2):S215-S220.
6. Gao SZ, Alderman EL, Schroeder JS, et al. Accelerated coronary vascular disease in the heart transplant patient: coronary arteriographic findings. J Am Coll Cardiol 1988; 12:334-340.
7. Avery RK. Cardiac-allograft vasculopathy. N Engl J Med 2003; 349:829-830.
8. Billingham ME. Histopathology of graft coronary artery disease. J Heart Lung Transplant 1992; 11 (3 Pt 2):S38-S44.
9. Radovancevic B, Birovlev S, Vega JD, et al. Inverse relationship between human leukocyte antigen match and development of coronary artery disease. Transplant Proc 1991; 23 (1 Pt 2):1144-1145.
10. Costanzo-Nordin MR. Cardiac allograft vasculopathy: relationship with acute cellular rejection and histocompatibility. J Heart Lung Transplant 1992; 11 (3 Pt 2):S90-S103.
11. Kerman RH, Kimball P, Scheinen S, et al. The relationship among donor-recipient HLA mismatches, rejection, and death from coronary artery disease in cardiac transplant recipients. Transplantation 1994; 57:884-888.
12. Hammond EH, Yowell RL, Price GD, et al. Vascular rejection and its relationship to allograft coronary artery disease. J Heart Lung Transplant 1992; 11 (3 Pt 2):S111-S119.
13. Zerbe T, Uretsky B, Kormos R, et al. Graft atherosclerosis: effects of cellular rejection and human lymphocyte antigen. J Heart Lung Transplant 1992; 11 (3 Pt 2):S104-S110.
14. Pietra BA. Transplant immunology 2003: simplified approach. Pediatr Clin North Am 2003; 50:1233-1259.
15. Guillot C, Guillonneau C, Mathieu P, et al. Prolonged blockade of CD40-CD40 ligand interactions by gene transfer of CD40Ig results in long-term heart allograft survival and donor-specific hyporesponsiveness, but does not prevent chronic rejection. J Immunol 2002; 168:1600-1609.
16. Szeto WY, Krasinskas AM, Kreisel D, et al. Depletion of recipient CD4+ but not CD8+ T lymphocytes prevents the development of cardiac allograft vasculopathy. Transplantation 2002; 73:1116-1122.
17. Gullestad L, Simonsen S, Ueland T, et al. Possible role of proinflammatory cytokines in heart allograft coronary artery disease. Am J Cardiol 1999; 84:999-1003.
18. Young JB, Windsor NT, Kleiman NS, et al. The relationship of soluble interleukin-2 receptor levels to allograft arteriopathy after heart transplantation. J Heart Lung Transplant 1992; 11 (3 Pt 2):S79-S82.
19. Nagano H, Mitchell RN, Taylor MK, et al. Interferon-γ deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts. J Clin Invest 1997; 100:550-557.
20. Wang Y, Burns WR, Tang PCY, et al. Interferon-γ plays a nonredundant role in mediating T-cell-dependent outward vascular remodeling of human coronary arteries. FASEB J 2004; 18:606-608.
21. Zhao XM, Frist WH, Yeoh TK, Miller GC. Confirmation of alternatively sliced platelet-derived growth factor-A chain and correlation with expression of PDGF receptor α in human cardiac allograft. Transplantation 1995; 59:605-611.
22. Zhao XM, Yeoh TK, Hiebert M, et al. The expression of acidic fibroblast growth factor (heparin-binding growth factor-1) and cytokine genes in human cardiac allograft and T cells. Transplantation 1993; 56:1177-1182.
23. Benza RL, Tallaj J. Cardiac allograft vasculopathy (chronic rejection). In: Kirklin JK, McFiffin DC, editors. Heart transplantation. Philadelphia: Churchill Livingstone; 2004. pp. 615-665.
24. Dunn MJ, Crisp SJ, Rose ML, et al. Anti-endothelial antibodies and coronary artery disease after cardiac transplantation. Lancet 1992; 339:1566-1570.
25. Shepard BL, French JE. Platelet adhesion in the rabbit abdominal aorta following the removal of the endothelium: a scanning and transmission electron microscopial study. Proc Soc Exp Biol Med 1971; 176:427-432.
26. DiCorleo PE, Gimbrone MA. Vascular endothelium. In: Fuster V, Ross R, Topol EJ, editors. Atherosclerosis and coronary artery disease. Philadelphia: Lippincott-Raven; 1996. pp. 387-389.
27. Koglin J, Glysing-Jensen T, Mudgett JS, Russell ME. Exacerbated transplant arteriosclerosis in inducible nitric oxide-deficient mice. Circulation 1998; 97:2059-2065.
28. Ravalli S, Szabolcs M, Albala A, et al. Increased immunoreactive endothelin-1 in human transplant coronary artery disease. Circulation 1996; 94:2096-2102.
29. Labarrere CA, Pitts D, Nelson DR, Faulk WP. Vascular tissue plasminogen activator and the development of coronary artery disease in heart-transplant recipients. N Engl J Med 1995; 333:1111-1116.
30. Subramanian AK, Quinn TC, Kickler TS, et al. Correlation of Chlamydia pneumoniae infection and severity of accelerated graft arteriosclerosis after cardiac transplantation. Transplantation 2002; 73:761-764.
31. Grattan MT, Moreno-Cabral CE, Starnes VA, et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989; 261:3561-3566.
32. Valantine HA, Gao SZ, Menon SG, et al. Impact of prophylactic immediate post transplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation 1999; 100:61-66.
33. Kato T, Chan MC, Gao SZ, et al. Glucose intolerance, as reflected by hemoglobin A1c level, is associated with the incidence and severity of transplant coronary artery disease. J Am Coll Cardiol 2004; 43:1034-1041. Investigated the effect of plasma hemoglobin A(1c) (HbA(1c)) on the development of transplant CAD.
34. Costanzo R, Naftel DC, Pritzker MR, et al. The Cardiac Transplant Research Database. Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors. J Heart Lung Transplant 1998; 17:744-753.
35. Botas J, Pinto FJ, Chenzbraun A, et al. Influence of preexisting donor coronary artery disease on the progression of transplant vasculopathy: an intravascular ultrasound study. Circulation 1995; 92:1126-1132.
36. Gao SZ, Alderman E, Schroeder J, Silverman JF. Accelerated coronary vascular disease in the heart transplant patient: coronary arteriographic findings. J Am Coll Cardiol 1988; 12:334-340.
37. Boffa G, Faggian G, Buja G. Coronary artery spasm in heart transplant recipients. J Heart Lung Transplant 1989; 8:154-158.
38. St Goar FG, Pinto FJ, Alderman EL, et al. Intracoronary ultrasound in cardiac transplant recipients: in vivo evidence of 'angiographically silent' intimal thickening. Circulation 1992; 85:979-987.
39. Kapadia SR, Ziada KM, L'Allier PL, et al. Intravascular ultrasound imaging after cardiac transplantation: advantage of multivessel imaging. J Heart Lung Transplant 2000; 19:167-172.
40. Aranda JM, Hill J. Cardiac transplant vasculopathy. Chest 2000; 118:1792-1800.
41. Spes CH, Mudra H, Schnaack SD, et al. Dobutamine stress echocardiography for non-invasive diagnosis of cardiac allograft vasculopathy: a comparison with angiography and intravascular ultrasound. Am J Cardiol 1996; 78:168-174.
42. Ramzy D, Rao V, Brahm J, et al. Cardiac allograft vasculopathy: a review. Can J Surg 2005; 48:319-327. Describes numerous areas of active CAV research.
43. Anguita M, Alonso-Pulpon L, Arizon J, et al. A comparison of the effectiveness of lovastatin therapy for hypercholesterolemia after heart transplantation between patients with and without pretransplant atherosclerotic CAD. Am J Cardiol 1994; 74:776-779.
44. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Eng J Med 1995; 333:621-627.
45. Mehra MR, Uber PA, Vivekananthan K, et al. Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival. J Am Coll Cardiol 2002; 40:1609-1614.
46. Ventura HO, Milani RV, Lavie CJ, et al. Cyclosporine-induced hypertension: efficacy of omega-3 fatty acids in patients after cardiac transplantation. Circulation 1993; 88 (Pt 2):II281-II285.
47. Schroeder JS, Gao SZ, Alderman EL, et al. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. N Engl J Med 1993; 328:164-170.
48. Mehra MR, Ventura HO, Smart FW, Stapleton DD. Impact of converting enzyme inhibitors and calcium entry blockers on cardiac allograft vasculopathy: from bench to bedside. J Heart Lung Transplant 1995; 14 (6 Pt 2):S246-S249.
49. Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant. Mycophenolate Mofetil Investigators Transplantation 1998; 66:507-515.
50. Schuurman HJ, Pally C, Weckbecker G, et al. SDZ RAD inhibits cold ischemia-induced vascular remodeling. Transplant Proc 1999; 31:1024-1025.
51. Cole OJ, Shehata M, Rigg KM. Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model. Transplant Proc 1998; 30:2200-2203.
52. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplant recipients. N Engl J Med 2003; 349:847-858.
53. Miniati DN, Robbins RC. Heart transplantation: a thirty year perspective. Annu Rev Med 2002; 53:189-205.
54. Hoyt G, Gollin G, Billingham M, et al. Effects of anti-platelet regimens in combination with cyclosporine on heart allograft vessel disease. Heart Transplant 1984; 4:54-56.
55. Muskett A, Burton NA, Eiuchwald EJ, et al. The effect of antiplatelet drugs on graft atherosclerosis in rat heterotopic cardiac allografts. Transplant Proc 1987; 4:74-75.
56. Gupta A, Moustapha A, Jacobsen D, et al. High homocysteine, low folate, and low vitamin B6 concentrations: prevalent risk factors for vascular disease in heart transplant recipients. Transplantation 1998; 65:544-550.